Skip to content
Clinical Trials – home
Not yet recruiting

A Phase 3 Study of PF-08653944 Monthly Injection to Evaluate Efficacy and Safety in Adults with Obstructive Sleep Apnea and Obesity Not Using PAP Therapy

Investigational
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

Adults who have Obstructive Sleep Apnea—a condition where the airway collapses during sleep and causes repeated pauses in breathing—and who are also classified as Overweight or Obesity may be invited to receive a monthly dose of a new medicine called berobenatide. The drug is given as a tiny amount injected under the skin (subcutaneous injection). Participants may also receive an inactive substance (placebo) that looks the same, so that neither the participants nor the study staff know which treatment is being given.

The study’s purpose is to find out whether berobenatide can lower the number of breathing interruptions compared with the placebo. The trial is designed as a randomized, double‑blind study, meaning participants are assigned by chance to one of the two groups and neither they nor the investigators know the assignment. Over the course of about a year, participants will receive the monthly injection, attend regular visits, and have simple tests such as measuring the Apnea–Hypopnea Index (AHI), which counts how many breathing pauses occur each hour of sleep, to see how the treatment affects their sleep breathing and related health outcomes.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Enrollment and Randomization

    After joining the study, you will be assigned at random to receive either berobenatide or a matching placebo. The assignment is double‑blind, so you will not know which one you receive.

    Randomization occurs shortly after the first study visit and determines the treatment you will receive for the entire trial.

  2. Step 2

    Baseline Assessments

    Before any medication is given, a series of measurements are taken to establish your starting values.

    Apnea–Hypopnea Index (AHI) is measured during an overnight sleep test; it counts breathing interruptions per hour.

    Your body weight, blood pressure, and a blood sample for high‑sensitivity C‑reactive protein (hs‑CRP) are collected.

    You will also complete questionnaires that evaluate sleep quality and physical function.

  3. Step 3

    First Monthly Injection

    You receive a subcutaneous (under the skin) injection of the study medication. The injection contains either berobenatide or the matching placebo.

    The exact dose is defined by the study protocol and is administered as a single injection once every month.

    This first injection marks the start of the 52‑week treatment period.

  4. Step 4

    Monthly Follow‑Up Visits

    Every month for the next 12 months you return to the clinic for a follow‑up visit.

    During each visit you receive the next monthly injection of the same study medication you were assigned at the start.

    The study staff checks your health, records any side effects, measures your weight and blood pressure, and may draw a small blood sample.

    These visits help ensure your safety and allow the study to track changes over time.

  5. Step 5

    Periodic Sleep‑Study Assessments

    At several points during the trial (for example at weeks 12, 24, 36, and 52) you undergo an overnight sleep study.

    The sleep study provides updated values for AHI and related scores such as the Sleep‑Related Breathing Disorder score (SASHB).

    These measurements are used to evaluate how the medication affects breathing events during sleep.

  6. Step 6

    Laboratory Assessments

    During selected visits, blood is drawn to measure hs‑CRP and other laboratory markers.

    These tests help assess inflammation and other safety parameters.

  7. Step 7

    Final Visit at Week 52

    At the end of the 52‑week period you attend a final study visit.

    The last monthly injection is given, and comprehensive assessments are performed, including a final sleep study for AHI, weight measurement, blood pressure check, and completion of the same questionnaires used at baseline.

    The data collected at this visit are used to determine the overall effect of berobenatide compared with placebo.

Who can join the trial?

4 criteria

  • Adults who are 18 years old or older.
  • Body mass index (BMI) of 27 kg/m² or higher at the screening visit. BMI is a number that compares your weight to your height to see if you are overweight.
  • Must have a previous diagnosis of moderate to severe obstructive sleep apnea. This means you have a condition where your breathing stops or becomes very shallow many times while you sleep, and it is considered more than mild.
  • Unable or unwilling to use positive airway pressure (PAP) therapy, and you must not have used any PAP device for at least 4 weeks before the screening. PAP therapy is a machine that blows air into your airway to keep it open while you sleep.

Who cannot join the trial?

10 criteria

  • Lost or gained more than 5% of your body weight in the past three months (about 90 days) before the screening.
  • Have been diagnosed with any form of diabetes (a condition where the body has trouble controlling blood sugar), except for gestational diabetes that has fully resolved after pregnancy.
  • Have a past history of pancreatitis, which means inflammation of the pancreas, whether it was a short‑term (acute) episode or a long‑term (chronic) problem.
  • Have you or a close family member ever had medullary thyroid carcinoma (MTC) (a type of thyroid cancer) or multiple endocrine neoplasia type 2 (MEN 2) (a genetic condition that can cause tumors in several hormone‑producing glands).
  • Have any sleep‑related conditions, treatments, or disorders that could interfere with measuring breathing problems from obstructive sleep apnea (OSA), such as:
    • Previous surgery on the airway (the passage that carries air to your lungs).
    • Sleep disorders that are not obstructive sleep apnea, like central sleep apnea.
    • Conditions that cause low breathing rates (hypoventilation disorders).
    • Use of sleep apnea treatments that do not involve a positive airway pressure machine (non‑PAP treatments).
    • Significant problems with the lungs, nerves, muscles, or facial bones that affect breathing.
    • Severe trouble sleeping (insomnia) or other important sleep disorders.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Berobenatide (PF‑08653944)
Berobenatide is an experimental drug that is given as a liquid that is injected under the skin (subcutaneous injection). In this study participants receive the injection once every month. The medication is being tested to see if it can lower the number of breathing interruptions that happen during sleep (apnea‑hypopnea events) in adults who have obstructive sleep apnea and who are overweight or obese, and who are not using a positive airway pressure machine. The goal is to find out whether berobenatide works better than a placebo in improving sleep breathing patterns and overall safety.

What is already known about the treatment

Berobenatide - Berobenatide is supplied as a clear solution for injection that is given subcutaneously once a month. It is an investigational peptide drug that is currently in Phase 3 clinical trials and has not yet received regulatory approval. The medication is being studied to treat obstructive sleep apnea in adults who are overweight or obese and do not use positive airway pressure therapy. It works by binding to a specific receptor and lowering the activity of a hormone that affects breathing control, and it is classified as a peptide receptor modulator.

Investigated diseases

  • Obstructive sleep apnea

    a condition where the airway collapses repeatedly during sleep, causing breathing pauses. These pauses lead to brief awakenings and reduced oxygen levels. Over time, the frequency of events can increase, making sleep less restorative. The condition often worsens with weight gain or aging.

  • Obesity

    a chronic condition characterized by excess body fat that accumulates over time. It typically develops gradually as calorie intake consistently exceeds energy expenditure. As weight increases, it can become more difficult to lose weight without intervention. The excess weight can affect many body systems and may lead to further health changes.

Trial detailsLast updated 21 Nov 2026
Age18+ yearsPhasePhase IIITrial ID2026-527014-23-00Protocol codeC6491021Estimated enrolment223 patientsSponsorPfizer Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.